Vesalic
London, United Kingdom· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
An AI-driven biotech using machine learning to discover novel oncology drug targets and therapeutics.
Oncology
Technology Platform
A proprietary AI and machine learning platform that integrates multi-omics and clinical data to identify novel oncology drug targets and predictive biomarkers.
Opportunities
The vast, growing datasets in oncology and unmet need for novel targets provide a rich substrate for AI to generate valuable, licensable discovery programs.
Risk Factors
High risk of platform validation, as AI-predicted targets may fail in biological validation or clinical development, a common challenge in the field.
Competitive Landscape
Faces intense competition from well-funded AI-biotech peers (e.g., Exscientia, Recursion) and large pharma's internal AI initiatives, all vying to prove the clinical value of their platforms.